Skip Ribbon Commands
Skip to main content
Sign In

26293 Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded (CMAPT)

Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded (CMAPT)
Test Code: CMAPTSO
Synonyms/Keywords

​aCGH
Array CGH
Array Comparative Genomic Hybridization
Oligonucleotide Array
Oligo Array
Single Nucleotide Polymorphism (SNP) Array
Whole Genome Array
Microarray
Molecular Karyotype
OncoScan
Oncology Array
Oncologic Array
Onc Array
Loss of Heterozygosity (LOH)
Copy Neutral Loss of Heterozygosity (cnLOH)
BRAF KIAA1549 Fusion
1p 19q Co-Deletion
Paraffin Embedded Tumor Array

Useful For

Genomic characterization of tumor for copy number imbalances and loss of heterozygosity

Assisting in the diagnosis and classification of malignant neoplasms

Evaluating the prognosis for patients with malignant tumors

Specimen Requirements
​ Submit only 1 of the following specimens:  ​
Specimen TypePreferred Container/TubeAcceptable Container/TubeSpecimen VolumeSpecimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​Tissue​Formalin-fixed, paraffin-embedded tumor tissue block
​Slides​10 Consecutive, unstained, 5-micron-thick sections placed on positively charged slides and 1 hematoxylin and eosin-stained slide
Collection Processing Instructions

A reason for referral and pathology report are required in order for testing to be performed. Send information with specimen. Acceptable pathology reports include working drafts, preliminary pathology or surgical pathology reports.

Specimen Stability Information
Specimen TypeTemperature
​Varies ​​Ambient (preferred)
​Refrigerated
Rejection Criteria
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability. 
Interference

This test is not approved by the FDA and it is best used as an adjunct to existing clinical and pathologic information.

This test does not detect balanced chromosome rearrangements such as reciprocal translocations, inversions, or balanced insertions.

This test does not detect point mutations, small deletions or insertions below the resolution of the assay, or other types of mutations such as epigenetic changes.

This test may not detect mosaic abnormalities in a minor proportion of cells, as such it is not recommended for minimal residual disease monitoring or for specimens with tumor proportions less than approximately 20% of sample.

The results of this test may reveal incidental findings unrelated to the original reason for referral.​

Performing Laboratory Information
Performing LocationDay(s) Test PerformedAnalytical TimeMethodology/Instrumentation
​Mayo Clinic Laboratories​Monday through Sunday​10-21 days​Chromosomal Microarray (CMA) Using Applied Biosystems (Affymetrix) Oncoscan
Reference Lab
Reference Range Information
Performing LocationReference Range
​Mayo Clinic Laboratories​An interpretive report will be provided. 
Interpretation

The interpretive report describes copy number changes and any loss of heterozygosity that may be associated with the neoplastic process. Abnormal clones with subclonal cytogenetic evolution will be discussed if identified.

The continual discovery of novel copy number variation and published clinical reports means that the interpretation of any given copy number change may evolve with increased scientific understanding.

Although the presence of a clonal abnormality usually indicates a neoplasia, in some situations it may reflect a benign or constitutional genetic change. If a genetic change is identified that is likely constitutional and clearly pathogenic (eg, XYY), follow-up with a medical genetics consultation may be suggested.

The absence of an abnormal clone may be the result of specimen collection from a site that is not involved in the neoplasm, or may indicate that the disorder is caused by a point mutation that is not detectable by chromosomal microarray (CMA).

CMA, FISH, and conventional cytogenetics are to some extent complementary methods. In some instances, additional FISH or conventional cytogenetic studies will be recommended to clarify interpretive uncertainties. 

Outreach CPTs
CPTModifier
(if needed)
QuantityDescriptionComments
​81277​1
Synonyms/Keywords

​aCGH
Array CGH
Array Comparative Genomic Hybridization
Oligonucleotide Array
Oligo Array
Single Nucleotide Polymorphism (SNP) Array
Whole Genome Array
Microarray
Molecular Karyotype
OncoScan
Oncology Array
Oncologic Array
Onc Array
Loss of Heterozygosity (LOH)
Copy Neutral Loss of Heterozygosity (cnLOH)
BRAF KIAA1549 Fusion
1p 19q Co-Deletion
Paraffin Embedded Tumor Array

Ordering Applications
Ordering ApplicationDescription
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
​ Submit only 1 of the following specimens:  ​
Specimen TypePreferred Container/TubeAcceptable Container/TubeSpecimen VolumeSpecimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​Tissue​Formalin-fixed, paraffin-embedded tumor tissue block
​Slides​10 Consecutive, unstained, 5-micron-thick sections placed on positively charged slides and 1 hematoxylin and eosin-stained slide
Collection Processing

A reason for referral and pathology report are required in order for testing to be performed. Send information with specimen. Acceptable pathology reports include working drafts, preliminary pathology or surgical pathology reports.

Specimen Stability Information
Specimen TypeTemperature
​Varies ​​Ambient (preferred)
​Refrigerated
Rejection Criteria
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability. 
Interference

This test is not approved by the FDA and it is best used as an adjunct to existing clinical and pathologic information.

This test does not detect balanced chromosome rearrangements such as reciprocal translocations, inversions, or balanced insertions.

This test does not detect point mutations, small deletions or insertions below the resolution of the assay, or other types of mutations such as epigenetic changes.

This test may not detect mosaic abnormalities in a minor proportion of cells, as such it is not recommended for minimal residual disease monitoring or for specimens with tumor proportions less than approximately 20% of sample.

The results of this test may reveal incidental findings unrelated to the original reason for referral.​

Useful For

Genomic characterization of tumor for copy number imbalances and loss of heterozygosity

Assisting in the diagnosis and classification of malignant neoplasms

Evaluating the prognosis for patients with malignant tumors

Reference Range Information
Performing LocationReference Range
​Mayo Clinic Laboratories​An interpretive report will be provided. 
Interpretation

The interpretive report describes copy number changes and any loss of heterozygosity that may be associated with the neoplastic process. Abnormal clones with subclonal cytogenetic evolution will be discussed if identified.

The continual discovery of novel copy number variation and published clinical reports means that the interpretation of any given copy number change may evolve with increased scientific understanding.

Although the presence of a clonal abnormality usually indicates a neoplasia, in some situations it may reflect a benign or constitutional genetic change. If a genetic change is identified that is likely constitutional and clearly pathogenic (eg, XYY), follow-up with a medical genetics consultation may be suggested.

The absence of an abnormal clone may be the result of specimen collection from a site that is not involved in the neoplasm, or may indicate that the disorder is caused by a point mutation that is not detectable by chromosomal microarray (CMA).

CMA, FISH, and conventional cytogenetics are to some extent complementary methods. In some instances, additional FISH or conventional cytogenetic studies will be recommended to clarify interpretive uncertainties. 

For more information visit:
Performing Laboratory Information
Performing LocationDay(s) Test PerformedAnalytical TimeMethodology/Instrumentation
​Mayo Clinic Laboratories​Monday through Sunday​10-21 days​Chromosomal Microarray (CMA) Using Applied Biosystems (Affymetrix) Oncoscan
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPTModifier
(if needed)
QuantityDescriptionComments
​81277​1
For most current information refer to the Marshfield Laboratory online reference manual.